Quantifying delay in access to new medical treatment: An application of risk advancement period methodology

Epidemiology

Volumn 15, Issue 2, 2004, Pages 202-207

  Krobot, Karl J ^a,d   Miller, William C ^a,b   Kaufman, Jay S ^a   Christensen, Dale B ^c   Preisser, John S ^a   Ibrahim, Michel A ^a  

^a IL   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

^d NONE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ERGOTAMINE DERIVATIVE; SUMATRIPTAN; SEROTONIN AGONIST;

ADULT; AGED; ARTICLE; FEMALE; GERMANY; HEALTH CARE ACCESS; HEALTH CARE POLICY; HEALTH INSURANCE; HIGH RISK POPULATION; HUMAN; MAJOR CLINICAL STUDY; MALE; METHODOLOGY; MIGRAINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK ASSESSMENT; CONFIDENCE INTERVAL; HEALTH SURVEY; MIDDLE AGED; PUBLIC HEALTH; TIME;

ADULT; AGED; CONFIDENCE INTERVALS; FEMALE; GERMANY; HEALTH STATUS INDICATORS; HUMANS; MALE; MIDDLE AGED; MIGRAINE DISORDERS; NATIONAL HEALTH PROGRAMS; SEROTONIN AGONISTS; SUMATRIPTAN; TIME FACTORS;

EID: 2442442162     PISSN: 10443983     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ede.0000112142.27474.ad     Document Type: Article

References (14)

1. Krobot KJ, Miller WC, Kaufman JS, et al. The disparity in access to new medication by type of health insurance: lessons from Germany. Med Care. In press.
2. Krobot KJ. Study II - characterization of the health-insurance-related hurdle to a pharmaceutical innovation in the second through the fourth year of the German Healthcare Structure Reform Act. In: Health Insurance-Related Access to Pharmaceutical Innovation in Germany. Methods and Applications [dissertation]. Chapel Hill, NC: University of North Carolina; 2001:84-109.
3. Edwards A, Elwyn G. How should effectiveness of risk communication to aid patients' decisions be judged? A review of the literature. Med Decis Making. 1999;19:428-434.
4. Edwards A, Elwyn G, Covey J, et al R. Presenting risk information - a review of the effects of 'framing' and other manipulations on patient outcomes. J Health Commun. 2001;6:61-82.
5. Klein WM. Objective standards are not enough: affective, self-evaluative, and behavioral responses to social comparison information. J Pers Soc Psychol. 1997;72:763-774.
6. Hux JE, Naylor CD. Communicating the benefits of chronic preventive therapy: does the format of efficacy data determine patients' acceptance of treatment? Med Decis Making. 1995;15:152-157.
7. Brenner H, Gefeller O, Greenland S. Risk and rate advancement periods as measures of exposure impact on the occurrence of chronic diseases. Epidemiology. 1993;4:229-236.
8. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics. 1988;44:1049-1060.
9. Liese AD, Hense HW, Brenner H, et al. Assessing the impact of classical risk factors on myocardial infarction by rate advancement periods. Am J Epidemiol. 2000;152:884-888.
10. Keil U, Liese AD, Hense HW, et al. Classical risk factors and their impact on incident non-fatal and fatal myocardial infarction and all-cause mortality in southern Germany. Results from the MONICA Augsburg cohort study 1984-1992. Monitoring Trends and Determinants in Cardiovascular Diseases. Eur Heart J. 1998;19:1197-1207.
11. Ford ES, DeStefano F. Risk factors for mortality from all causes and from coronary heart disease among persons with diabetes. Findings from the National Health and Nutrition Examination Survey I Epidemiologic Follow-up Study. Am J Epidemiol. 1991;133:1220-1230.
12. Gross MLP, Dowson AJ, Deavy L, et al. Impact of oral sumatriptan 50 mg on work productivity and quality of life in migraineurs. British Journal of Medical Economics. 1996;10:231-246.
13. Cortelli P, Dahlof C, Bouchard J, et al. A multinational investigation of the impact of subcutaneous sumatriptan. III: Workplace productivity and non-workplace activity. Pharmacoeconomics. 1997;11(suppl 1):35-42.
14. Mushet GR, Miller D, Clements B, et al. Impact of sumatriptan on workplace productivity, nonwork activities, and health-related quality of life among hospital employees with migraine. Headache. 1996;36:137-143.